Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197632 | 0.94 | KMT2A (0.76) | KMT2ATSHRKCNH2DRD2DRD4 | |
| Methyl Alcohol SCHEMBL27541418 | 0.91 | KMT2A (0.71) | KMT2ATSHRKCNH2DRD2DRD4 | |
| Dimethylamine SCHEMBL3445328 | 0.89 | KMT2A (0.74) | KMT2ATSHRKCNH2DRD2DRD4 | |
| SCHEMBL196962 | 0.89 | KMT2A (0.68) | KMT2AKCNH2DRD2DRD4LMNA | |
| SCHEMBL11663051 | 0.86 | TSHR (0.72) | KMT2ATSHRLTA4H | |
| SCHEMBL9774806 | 0.85 | DRD2 (0.60) | KMT2AKCNH2DRD2DRD4LMNA | |
| SCHEMBL6677146 | 0.84 | TSHR (0.76) | TSHRLTA4H | |
| SCHEMBL4208924 | 0.84 | TSHR (0.76) | TSHRLTA4H | |
| SCHEMBL17138169 | 0.84 | TSHR (0.76) | TSHRLTA4H | |
| SCHEMBL3905859 | 0.84 | TSHR (0.76) | TSHRLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
| EP-0840725-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1998-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | KCNJ2, KCNH2, CACNA1E | KMT2A 3048/4885TSHR 1243/4885KCNH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.